Company / Operating Cash Flow
Edesa Biotech, Inc. Operating Cash Flow History
FY2014-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$5.0M
FY2021
5-year range
-$5.0M / -$4.3M
FY2017-FY2021
Trend
-2.9%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 5 consecutive years, from -$3M in FY2015 to -$5M in FY2021.
Based on SEC 10-K filings.
-$5M in FY2021.
Declined from -$5M to -$5M over the past 3 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Edesa Biotech, Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2021, operating cash flow decreased 2.9% year-over-year.
- Peak operating cash flow was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | -$5.0M | -2.9% |
| FY2020 | -$4.8M | -3.1% |
| FY2018 | -$4.7M | -6.5% |
| FY2017 | -$4.4M | -3.4% |
| FY2016 | -$4.3M | -52.6% |
| FY2015 | -$2.8M | +29.2% |
| FY2014 | -$3.9M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026